Steve,
Presumably Lysonix over estimated short term demand. None-the-less, MSON has said that it expects the most recent order from Lysonix, for $3,000,000 to be shipped in the current quarter: I'm guessing that this has/will happen. So the current quarter should be fine. There is MSON's original core business, and the $1,500,000 first contract from U.S. Surgical which could also go to the current quarter. Plus there is that $1,100,000 contract for air pollution equipment at a semiconductor plant.
For the Jan-Mar '98 quarter, the lack of Lysonix revenue will be counter-balanced by a good portion of the $3,800,000 U.S. Surgical order (just guessing). Then, guessing again, the next quarter should see more orders from U.S. Surgical and new orders from Lysonix? Bottom line, IMO, MSON, looks to be a nice growing hi-tech medical instruments company, with other interests, and now at a pretty good price.
John |
